Novo Nordisk (NVO) said Thursday that Executive Vice President of Commercial Strategy and Corporate Affairs Camilla Sylvest has decided to depart.
The company said EVP of Rare Disease Ludovic Helfgott will assume the responsibility for product and portfolio strategy, while Senior Vice President of Product Supply Emerging Technologies Thilde Hummel Bogebjerg was promoted to EVP of quality, IT and environmental affairs.
EVP of People and Organization Tania Sabroe is assuming the additional responsibility for global communication, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.